Dermata Therapeutics -CW26DRMAWPreferred / convertible
13F holders, Q4 2025 (December 31)2holders −1
0new positions
1sold out
$1.14avg. 13F price*
At the end of Q4 2025, 2 institutions reported holding Dermata Therapeutics -CW26 (DRMAW) in their 13F filings, down 1 from Q3 2025. 0 opened new positions and 1 sold out. The largest holders were Boothbay Fund Management, LLC ($28K) and Susquehanna International Group, LLP ($253).
- Company
- Dermata Therapeutics -CW26
- CUSIP
- 249845116
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $22 |
All 13F filers, Q3 2025 → Q4 2025: 2,495 shares bought and 1,279 shares sold, net +1,216 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Boothbay Fund Management, LLC | — | No change | 12,000 | $28K |
| Susquehanna International Group, LLP | — | Add +24.5% | 12,671 | $253 |
"% of holder's portfolio" is DRMAW's weight in each manager's 13F, not the share of Dermata Therapeutics -CW26 the manager owns.